Organization
Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma
2 abstracts
Abstract
ASSESSMENT OF FLARES IN LUPUS (SLE) PATIENTS IN A PLACEBO-CONTROLLED RANDOMIZED PHASE II/III STUDY OF RITUXIMAB (EXPLORER) Org: Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma, Medicine/Rheum, NYU, New York, Rheumatology, North Shore-LIJ Health System, Lake Success, Internal Medicine, Univ. Kansas, Kansas City, United States, Immunity-Infection, Univ. Birmingham, Birmingham, United Kingdom,
Abstract
78-WEEK SAFETY DATA FROM THE RANDOMIZED, DOUBLE-BLIND PHASE II/III EXPLORER STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TREATED WITH RITUXIMAB Org: Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma, Internal Medicine, U. Kansas, Kansas, Rheumatology, U. Chicago, Chicago, Rheumatology, N. Shore LIJ Health System, Lake Success, Rheumatology, Alameda Medical Ctr, Oakland,